Publications by authors named "Larry D Anderson"

Claim this Profile
P
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response.
Rahul Banerjee, Gurbakhash Kaur, Beatrice M Razzo, Andrew J Portuguese, Surbhi Sidana, Larry D Anderson

Am J Hematol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL Amyloidosis.
Matthew J Rees, Jack Khouri, Ariel F Grajales-Cruz, Saurabh S Zanwar, Utkarsh Goel, Larry D Anderson

Am J Hematol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia.
Gliceida M Galarza Fortuna, Lauren Peres, Elena Nazarenko, Andre De Menezes Silva Corraes, Vanna N Hovanky, Larry D Anderson

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.
Beatrice M Razzo, Shonali Midha, Andrew J Portuguese, Ariel F Grajales-Cruz, Andre De Menezes Silva Corraes, Larry D Anderson

Blood Cancer Discov· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience.
Aimaz Afrough, Danai Dima, Beatrice Razzo, Utkarsh Goel, Aishwarya Sannareddy, Larry D Anderson

Blood Cancer J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.
Binod Dhakal, Othman S Akhtar, David Fandrei, Alexandria Jensen, Rahul Banerjee, Larry D Anderson

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses.
Laahn Foster, Larry D Anderson, Alfred Chung, Chakra P Chaulagain, Erin Pettijohn

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant.
Benjamin A Derman, Jennifer Cooperrider, Anna Pula, Heidi Simmons, Tadeusz Kubicki, Larry D Anderson

Hemasphere· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing Selection of Bridging Therapies Prior to CAR-T Therapy Administration for Multiple Myeloma: Clinical Pearls From an Expert Roundtable.
Sikander Ailawadhi, Larry D Anderson, Binod Dhakal, Leyla Shune, Douglas W Sborov

Clin Lymphoma Myeloma Leuk· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment.
Danai Dima, Aimaz Afrough, Utkarsh Goel, Ariel F Grajales-Cruz, Jack Khouri, Larry D Anderson

Blood Adv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma.
Surbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, Ruta Brazauskas, Temitope Oloyede, Larry D Anderson

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.
Danai Dima, Mariola A Vazquez-Martinez, James A Davis, Utkarsh Goel, Aimaz Afrough, Larry D Anderson

Blood Cancer J· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the Affordable Care Act and Medicaid Expansion Among Patients With HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphomas.
Naveen Premnath, Yulun Liu, Heather Reves, Urvashi Pandey, Rasmi G Nair, Julia Anderson, Larry D Anderson

JCO Oncol Pract· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Doris K Hansen, Lauren C Peres, Danai Dima, Alicia Richards, Leyla Shune, Larry D Anderson

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.
Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer, Larry D Anderson

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025.
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson, Muhamed Baljevic

J Natl Compr Canc Netw· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.
Oren Pasvolsky, Danai Dima, Lei Feng, Wenli Dong, Tiffany Richards, Larry D Anderson

Blood Cancer J· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study.
Othman Salim Akhtar, Temitope Oloyede, Ruta Brazauskas, Aimaz Afrough, Hamza Hashmi, Larry D Anderson

Blood Adv· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Doris K Hansen, Lauren C Peres, Danai Dima, Alicia Richards, Leyla Shune, Larry D Anderson

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis.
Sharlene Dong, Rahul Banerjee, Adeel M Khan, Mengru Wang, Xiaoliang Wang, Larry D Anderson

Blood Cancer J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study.
Ashraf Badros, Laahn Foster, Larry D Anderson, Chakra P Chaulagain, Erin Pettijohn

Blood· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma.
Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves, Larry D Anderson

Future Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unusual paraneoplastic neurological presentation associated with multiple myeloma.
Anik Amin, Enrique Chiu Han, Rumyar Ardakani, Larry D Anderson

BMJ Case Rep· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy.
Danai Dima, Utkarsh Goel, Aishwarya Sannareddy, Nnaemeka Ibeh, Fauzia Ullah, Larry D Anderson

Hematol Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.
Ajai Chari, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves, Larry D Anderson

Blood Cancer J· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis